[The assessment of symptomatic burden among Ph/BCR- ABL negative myeloproliferative neoplasm patients]

Zhonghua Xue Ye Xue Za Zhi. 2016 Jan;37(1):26-9. doi: 10.3760/cma.j.issn.0253-2727.2016.01.005.
[Article in Chinese]

Abstract

Objective: To investigate the value of myeloproliferative neoplasms Symptom Assessment Form total symptom score (MPN-SAF-TSS)in assessing constitutional symptoms among Ph/BCR- ABL negative myeloproliferative neoplasm (MPN)patients.

Methods: A cohort of 628 MPN patients were evaluated by MPN- SAF- TSS.

Results: Fatigue was the most common symptom (76.0%, 76.2%vs 89.9%)and the highest average severity of all the symptoms (3.46±2.97, 3.47±2.99vs 4.74±3.04 scores)among polycythemia vera (PV), essential thrombocythemia (ET)and primary myelofibrosis (PMF)patients. Using the MPN- SAF- TSS analysis, PMF patients showed highest burden of symptoms (28.9 ± 19.1), followed by PV patients (19.2 ± 16.8), and finally ET patients (17.1 ± 15.3). Instinct differences were observed between PMF and PV patients (χ(2)=6.371,P=0.021), PMF and ET patients (χ(2)= 14.020,P<0.001). No significant difference was found between PV and ET patients (χ(2)=2.281,P=0.191).

Conclusion: MPN- SAF- TSS was effective in evaluating the symptomatic burden among Ph/BCRABL negative MPN patients and could be used for serial assessment in this clinical setting.

目的: 评估Ph染色体和BCR-ABL阴性骨髓增殖性肿瘤(MPN)患者体质性症状负荷。

方法: 用骨髓增殖性肿瘤总症状评估量表(MPN-SAF-TSS)对628例MPN患者进行现场调查。

结果: 疲劳在真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)患者中的症状负荷和发生率均最高[分别为(3.46±2.97)、(3.47±2.99)、(4.74±3.04)分和76.0%、76.2%、89.9%]。患者的总症状负荷由高到低依次为PMF、PV、ET[分别为(28.9±19.1)、(19.2±16.8)、(17.1±15.3)分],PMF与PV、ET比较差异均有统计学意义(χ2=6.371,P=0.021;χ2=14.020,P<0.001),PV与ET之间差异无统计学意义(χ2=2.281,P=0.191)。

结论: MPN-SAF-TSS评估量表可有效评估MPN患者体质性症状,PV、ET和PMF患者中PMF的总症状负荷最高,用MPN-SAF-TSS评估量表进行症状评估应列为MPN治疗研究的评价指标。

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / diagnosis*
  • Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / physiopathology
  • Polycythemia Vera / complications*
  • Primary Myelofibrosis / complications*
  • Thrombocythemia, Essential / complications*

Grants and funding

基金项目:国家自然科学基金(81270585、81470297、81370611、81530008)